Skip Ribbon Commands
Skip to main content

Chemoembolization Adopting Polyethylene Glycol Drug-Eluting Embolics Loaded With Doxorubicin for the Treatment of Hepatocellular Carcinoma



Data collected included tumor response (at 1, 3, and 6 months), type and intensity grade of adverse events, and quality of life (QOL) analysis. 

Quality of Life 

  • QOL analysis at 1, 3, and 6 months after treatment showed that physical and social functioning were improved for most of the patients. 


  • There were no complications during the TACE procedure, which was well tolerated by all of the patients 
  • The most reported AEs of grade 1 or 2 were: fever (33%), elevated liver enzymes (17%), and pain (33%). These AEs resolved without complications. 
  • No grade 3 or 4 AEs were reported.


These data suggest that PEG embolics are efficacious and safe for the treatment of HCC, as indicated by their good tolerability, QOL scores, and high tumor response.